Natallia Laptseva, Dominik C Benz, Rahel Schwotzer, Andreas J Flammer
{"title":"Cardiac amyloidosis.","authors":"Natallia Laptseva, Dominik C Benz, Rahel Schwotzer, Andreas J Flammer","doi":"10.57187/s.4186","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and AL amyloidosis (caused by abnormal immunoglobulin light chains). Cardiac amyloidosis causes typical signs and symptoms of heart failure. Diagnosis involves a combination of imaging tests such as echocardiography and cardiac magnetic resonance imaging, as well as nuclear imaging scans and tissue biopsies to confirm the presence of amyloid deposits in the heart. Treatment of cardiac amyloidosis depends on the type and severity of the disease and includes medications to manage symptoms as well as treatments targeting the underlying cause of amyloidosis. Importantly, cardiac amyloidosis is a serious condition requiring specialised care from a multidisciplinary team including cardiologists and haematologists as well as other specialists familiar with the management of this rare disease. This is crucial, as early diagnosis and treatment are important for improving outcomes.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"4186"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.4186","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and AL amyloidosis (caused by abnormal immunoglobulin light chains). Cardiac amyloidosis causes typical signs and symptoms of heart failure. Diagnosis involves a combination of imaging tests such as echocardiography and cardiac magnetic resonance imaging, as well as nuclear imaging scans and tissue biopsies to confirm the presence of amyloid deposits in the heart. Treatment of cardiac amyloidosis depends on the type and severity of the disease and includes medications to manage symptoms as well as treatments targeting the underlying cause of amyloidosis. Importantly, cardiac amyloidosis is a serious condition requiring specialised care from a multidisciplinary team including cardiologists and haematologists as well as other specialists familiar with the management of this rare disease. This is crucial, as early diagnosis and treatment are important for improving outcomes.
心脏淀粉样变性是一种以淀粉样蛋白在心脏组织中积聚为特征的疾病。淀粉样变性有多种类型,但影响心脏的最常见类型是 ATTR 淀粉样变性(由转甲状腺素蛋白引起)和 AL 淀粉样变性(由异常免疫球蛋白轻链引起)。心脏淀粉样变性会导致典型的心力衰竭症状和体征。诊断需要结合超声心动图和心脏磁共振成像等影像学检查,以及核成像扫描和组织活检,以确认心脏中是否存在淀粉样蛋白沉积。心脏淀粉样变性的治疗取决于疾病的类型和严重程度,包括控制症状的药物以及针对淀粉样变性潜在病因的治疗。重要的是,心脏淀粉样变性是一种严重的疾病,需要多学科团队的专业治疗,包括心脏病专家、血液学专家以及熟悉这种罕见疾病治疗的其他专家。这一点至关重要,因为早期诊断和治疗对改善预后非常重要。
期刊介绍:
The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.